<?xml version="1.0" encoding="utf-8"?>
    
            

    
        



    <rss xmlns:content="http://purl.org/rss/1.0/modules/content/"  version="2.0">
        <channel>
            <title>Recently Published About HMA</title>
            <link>https://www.hma.eu//rss/recently-published-about-hma.html</link>
            <description>New contents from the website www.hma.eu. Category: Recently Published About HMA</description>
            <language>en</language>
            <copyright>Heads of Medicines Agencies</copyright>
            <pubDate>Fri, 29 May 2026 09:35:03 +0200</pubDate>
            
                <item>
                    <title><![CDATA[CTCG Members and Alternates]]></title>
                    <description><![CDATA[CTCG Members and Alternates are nominated by each EU/EEA National Competent Authorities (NCA) and represent the NCA.The Chair and the Vice-Chair of the CTCG are elected amongst the members for a period of three years. Currently CTCG is chaired by Marianne Lunzer, PhD (AGES MEA, Austria) and vice-chaired by Monique Al, PhD (CCMO, Netherlands)The secretariat is supported by the EMA and an expert from an NCA. The secretariat acts as the contact point for the group.The EMA and the Commission attend the meetings as observers.Representatives from other interested parties and national experts may be consulted and invited to attend the CTCG meetings on an ad hoc basis.
List of CTCG Members and Alternates

Member StateRoleMember NameAT - AustriaChair/MemberMarianne LunzerAT - AustriaAlternateJudith SecklehnerBE - BelgiumMember Anne Lenaers BE - BelgiumAlternate Nele SteensBG - BulgariaMember Ivelina GushlekovaBG - BulgariaAlternate Ivan TodorovCY - CyprusMemberEleni GeorgiadouCY - CyprusAlternateTheognosia PatsaledouCZ - Czech RepublicMember Eva Hrušková Reinová CZ - Czech RepublicAlternateJan NemecekDE - Germany (BfArM)MemberClaudia Riedel DE - Germany (BfArM)AlternateSarah Heil DE - Germany (PEI)MemberSusanne LerchDE - Germany (PEI)Vice-Chair/AlternateAndreas BonertzDK - DenmarkMemberLene Grejs PetersenDK - DenmarkAlternatePernille SterlingEE - EstoniaMemberKeiu HeinlaEE - EstoniaAlternateIngrid KiiskES - SpainMemberJuan Estévez Álamo ES - SpainAlternateLaura Lavin de JuanFI - FinlandMemberMarita Kailajärvi FI - FinlandAlternatePirjo InkiFR - FranceMemberCorinne KigerGR - GreeceMemberLeonidas KlironomosHR - Croatia (HALMED)MemberMaja PuklekHR - Croatia (HALMED)Alternate Ivana Kosier MihalicHR - Croatia (Miz)MemberIvana Matelic HR - Croatia (Miz)  Alternate Nikolina JozancHU - HungaryMemberÁgnes Zita Hajdú HU - HungaryAlternateHuba Eleőd IE - IrelandMemberClaire Temple IE - Ireland   Alternate  Tracy Keane IS - IcelandMemberAgnes Engilráð Scheving IS - IcelandAlternateUnnur IngólfsdóttirIT - ItalyMemberSandra PetragliaIT - ItalyAlternateDiego Alejandro DriLI - LiechtensteinMemberVlasta ZavadovaLT - LithuaniaMemberArūnas Vaitkevičius LT - LithuaniaAlternateEglė Daniulevičiūtė LU - LuxembourgMemberEdwige ChokotéLU - LuxembourgAlternateDounia BouzidLV - LatviaMemberJana MiglinieceLV - LatviaAlternateVita Berzina MT - MaltaMemberJohn Joseph BorgMT - MaltaAlternateBenjamin MicallefNL - NetherlandsMemberMonique AlNL - NetherlandsAlternatePaula VossebeldNO - NorwayMemberIngvild Aaløkken NO - NorwayAlternateIngvild Løberg Tangen PL - PolandMemberEwa Ołdak PL - PolandAlternateAgnieszka DzierwaPT - PortugalMemberJoel PassarinhoPT - PortugalAlternateSusana MarquesRO - RomaniaMemberMirela Vîță RO - RomaniaAlternateSilviu Istrate SE - SwedenMemberGunilla Andrew-Nielsen SE - SwedenAlternateAnn Marie Janson LangSI - SloveniaMemberMaja SkofSI - SloveniaAlternateJurij ŽelSK - SlovakiaMemberJana Grobarčík BallekováSK - SlovakiaAlternateLenka Igazová]]></description>
                    <link>https://www.hma.eu//about-hma/working-groups/clinical-trials-coordination-group/clinical-trials-coordination-group.html#c7043</link>
                    <guid>https://www.hma.eu//about-hma/working-groups/clinical-trials-coordination-group/clinical-trials-coordination-group.html#c7043</guid>
                    <pubDate>Thu, 04 Aug 2022 11:13:00 +0200</pubDate>
                </item>
            
                <item>
                    <title><![CDATA[]]></title>
                    <description><![CDATA[CMDhCMDvMRI Product Index - HUMMRI Product Index - VETMedicines Approval SystemCompassionate Use ProgrammesAvailability of Medicines]]></description>
                    <link>https://www.hma.eu//about-hma.html#c3847</link>
                    <guid>https://www.hma.eu//about-hma.html#c3847</guid>
                    <pubDate>Thu, 01 Jan 1970 01:00:00 +0100</pubDate>
                </item>
            
                <item>
                    <title><![CDATA[Working Groups Human]]></title>
                    <description><![CDATA[Working Groups Human
Clinical Trials Coordination Group (CTCG)
EU-Innovation Network (EU-IN)
DARWIN EU]]></description>
                    <link>https://www.hma.eu//about-hma/working-groups.html#c4160</link>
                    <guid>https://www.hma.eu//about-hma/working-groups.html#c4160</guid>
                    <pubDate>Wed, 02 Jan 2013 15:53:00 +0100</pubDate>
                </item>
            
                <item>
                    <title><![CDATA[Working Groups Joint]]></title>
                    <description><![CDATA[Working Groups Joint
Benchmarking of European Medicines Agencies Steering Group (BEMA SG)
EU Network Training Centre (EU NTC)
Homeopathic Medicinal Products Working Group (HMPWG)
HMA Substances Validation Group (SVG)
The Network Portfolio Advisory Group (NPAG)
The Network ICT Advisory Committee (NICTAC)
HMA/EMA Joint Audit Programme (JAP)
HMA Working Group of Biosimilars (BSWG)
Working Group of Communication Professionals (WGCP)
Working Group of Enforcement Officers (WGEO)
Working Group of Quality Managers (WGQM)
European Medicines Agencies Co-operation of Legal and Legislative Issues (EMACOLEX)
Regulatory Optimisation Group (ROG)
HMA-EMA Network Data Steering Group (NDSG)
HMA HRM and L&D
Pharmaceuticals in the Environment (PiE)]]></description>
                    <link>https://www.hma.eu//about-hma/working-groups.html#c4159</link>
                    <guid>https://www.hma.eu//about-hma/working-groups.html#c4159</guid>
                    <pubDate>Thu, 01 Jan 1970 01:00:00 +0100</pubDate>
                </item>
            
                <item>
                    <title><![CDATA[HMA PERMANENT SECRETARIAT]]></title>
                    <description><![CDATA[HMA PERMANENT SECRETARIATThe HMA Permanent Secretariat (HMA PS) is the team of appointed international advisers from six national competent authorities. They are strategy partners to HMA Management Group. The HMA PS translates HMA & HMA MG strategic initiatives into operational results by driving execution, collaboration and progress on the initiatives across all Heads of Medicines Agencies. 
The team is:
Carmen Gallego López-Jurado (AEMPS, Spain) | 
David Obranovič (JAZMP, Slovenia) | 
Marta Toma (AIFA, Italy ) | LinkedIn
Hannes Eintrei (SMPA, Sweden) | LinkedIn
Annalise Attard (MMA, Malta) | LinkedIn
Birgitte Faber (DKMA, Denmark) | LinkedIn
In case of queries, please contact us: ps@hma.eu]]></description>
                    <link>https://www.hma.eu//about-hma/structure.html#c2521</link>
                    <guid>https://www.hma.eu//about-hma/structure.html#c2521</guid>
                    <pubDate>Thu, 01 Jan 1970 01:00:00 +0100</pubDate>
                </item>
            
                <item>
                    <title><![CDATA[]]></title>
                    <description><![CDATA[HMA MANAGEMENT GROUP
The Heads of Medicines Agencies (HMA) Management Group, as endorsed during the Irish Presidency in 2004, has as its main-objectives the co-ordination and facilitation of the operation of HMA, and the supervision and management of the HMA Permanent Secretariat.
The current composition of the HMA Management Group is: 
María Jesús Lamas Díaz (AEMPS, Spain) - Chair  | biographyMomir Radulović (JAZMP, Slovenia) - Vice Chair | biographyRui Santos Ivo (INFARMED, Portugal; Chair EMA Management Board) | biographyThomas Heberer (BVL, Germany) | biographyGünter Waxenecker (AGES, Austria) | biographyKarl Broich (BfArM, Germany) | biographyFranck Foures (ANSES, France) | biographyAimad Torqui - co-opted (CBG-MEB, Netherlands; Vice-chair EMA Management Board) | biographyPresidency of the EU Council: Cyprus| Helena Panayiotopoulou (Ministry of Health)]]></description>
                    <link>https://www.hma.eu//about-hma/structure.html#c81</link>
                    <guid>https://www.hma.eu//about-hma/structure.html#c81</guid>
                    <pubDate>Tue, 13 Dec 2022 15:25:00 +0100</pubDate>
                </item>
            
                <item>
                    <title><![CDATA[FAST-EU Pilot Demonstrates Europe's Capacity for Accelerated and Coordinated Clinical Trial Authorisation]]></title>
                    <description><![CDATA[Three months into the pilot, 15 multinational clinical trials are progressing under accelerated timelines, with the first three procedures completed within the 70-day target
The Clinical Trials Coordination Group (CTCG) operating under the umbrella of the Heads of Medicines Agencies (HMA), and MedEthics EU under the auspices of the European Commission, today publish the first interim results of the FAST-EU pilot initiative (Facilitating and Accelerating Strategic Clinical Trials in the EU).
The pilot already applies the new accelerated procedure and mechanisms proposed by the Commission in the revision of the Clinical Trial Regulation in the Biotech Act, and thus serves as an early operational testbed for the revised clinical trial authorisation procedure. This new procedure aims to deliver a shorter, simpler and more predictable approval process. It does so while maintaining the highest standards of participant safety and data quality. 
Background
Launched in February 2026, FAST-EU is a voluntary pilot implemented within the framework of Regulation (EU) No 536/2014 (Clinical Trials Regulation, CTR). It aims to accelerate the coordinated assessment and authorisation of multinational clinical trial applications across Member States, while fully maintaining scientific, safety and ethical standards. FAST-EU operates entirely within the Clinical Trials Information System (CTIS) and does not alter the legal rights or obligations of any party.
The pilot serves as a practical proof of concept for the European Commission's proposal for an EU Biotech Act, demonstrating the feasibility of the streamlined and time-bound authorisation model for clinical trials. It is also a testimony of the strong commitment of Member States and sponsors to its implementation.
Strong Demand from Sponsors
In the first three months of operation, the FAST-EU Coordination Office received 68 Expressions of Interest from sponsors across Europe and internationally. Of these, 15 procedures were selected for inclusion in the pilot - three in February, four in March, four in April, and four in May 2026. The volume of applications exceeded the originally planned pilot capacity of two procedures per month, reflecting both the strong interest from the sponsor community and the willingness of Member States to step up to the challenge of increased demand.
The 15 selected trials cover a broad range of therapeutic areas, including oncology and haematology (7 trials), neurology and neurodegenerative diseases (2), cardiovascular and pulmonary vascular disease (2), and immunology and inflammatory disease (2). Trials span all development phases, from Phase I to Phase III, and involve on average 7.33 participating Member States per procedure, with individual trials involving up to 14 Member States. 
First Completed Procedures Confirm Feasibility of 70-Day Target
Three procedures have been completed to date, all meeting or closely approximating the 70-calendar-day target set by FAST-EU*. These results demonstrate that the 70-day timeline is operationally achievable across a diverse range of trial types, indication areas, and Member State constellations. 
Participating Member States and RMS Distribution
Twenty-six Member States and EEA countries are participating in FAST-EU. Reporting Member State distribution reflects the pan-European character of the initiative. RMS roles completed or ongoing include Italy, Denmark, the Netherlands, Germany (PEI), Finland, Poland, Sweden, Spain, Belgium, Norway, and the Czech Republic - with Romania, Hungary, Austria, and Portugal planned for upcoming procedures.
Relevance for the EU Biotech Act
he FAST-EU pilot was conceived in part as a proof of concept for the accelerated and coordinated clinical trial authorisation model anticipated under the EU Biotech Act. The pilot's timeline architecture - parallel validation, timelines based on full weeks, a single consolidated RFI round for Part I and a 70-day overall target - closely mirrors the  European Commission proposal for a revised authorisation procedure in the Biotech Act, aimed at creating a more competitive, agile and predictable European regulatory environment for clinical research.The interim results support the conclusion that this model is operationally feasible within the existing CTR framework, even where certain functionalities such timelines and separate validation processes are not yet supported by CTIS infrastructure. 
Next Steps
Ongoing evaluation will include qualitative findings from structured interviews with Reporting Member States on coordination effort, application of the reliance principle, and challenges for integration of Ethics Committees. A full pilot report will be published upon conclusion.
Sponsors wishing to submit an Expression of Interest for the FAST-EU pilot may contact the FAST-EU Coordination Office at FAST-EU@hma.eu. Further information is available in the FAST-EU External Guidance for Sponsors (Version 1.2, April 2026), published on the CTCG website.
The Clinical Trials Coordination Group (CTCG) is a standing working group of the Heads of Medicines Agencies (HMA), responsible for the operational implementation of the EU Clinical Trials Regulation. MedEthics EU under the auspices of the European Commission is the corresponding coordination body for Ethics Committees across the EU/EEA.
1For one trial a deviation of one day related to the Easter public holiday period was noted and documented.]]></description>
                    <link>https://www.hma.eu//about-hma/recently-published.html#c7880</link>
                    <guid>https://www.hma.eu//about-hma/recently-published.html#c7880</guid>
                    <pubDate>Wed, 20 May 2026 13:27:51 +0200</pubDate>
                </item>
            
                <item>
                    <title><![CDATA[CTCG News and Events]]></title>
                    <description><![CDATA[FAST-EU Pilot Demonstrates Europe's Capacity for Accelerated and Coordinated Clinical Trial Authorisation
Three months into the pilot, 15 multinational clinical trials are progressing under accelerated timelines, with the first three procedures completed within the 70-day target
The Clinical Trials Coordination Group (CTCG) operating under the umbrella of the Heads of Medicines Agencies (HMA), and MedEthics EU under the auspices of the European Commission, today publish the first interim results of the FAST-EU pilot initiative (Facilitating and Accelerating Strategic Clinical Trials in the EU).
The pilot already applies the new accelerated procedure and mechanisms proposed by the Commission in the revision of the Clinical Trial Regulation in the Biotech Act, and thus serves as an early operational testbed for the revised clinical trial authorisation procedure. This new procedure aims to deliver a shorter, simpler and more predictable approval process. It does so while maintaining the highest standards of participant safety and data quality. 
Background
Launched in February 2026, FAST-EU is a voluntary pilot implemented within the framework of Regulation (EU) No 536/2014 (Clinical Trials Regulation, CTR). It aims to accelerate the coordinated assessment and authorisation of multinational clinical trial applications across Member States, while fully maintaining scientific, safety and ethical standards. FAST-EU operates entirely within the Clinical Trials Information System (CTIS) and does not alter the legal rights or obligations of any party.
The pilot serves as a practical proof of concept for the European Commission's proposal for an EU Biotech Act, demonstrating the feasibility of the streamlined and time-bound authorisation model for clinical trials. It is also a testimony of the strong commitment of Member States and sponsors to its implementation.
Strong Demand from Sponsors
In the first three months of operation, the FAST-EU Coordination Office received 68 Expressions of Interest from sponsors across Europe and internationally. Of these, 15 procedures were selected for inclusion in the pilot - three in February, four in March, four in April, and four in May 2026. The volume of applications exceeded the originally planned pilot capacity of two procedures per month, reflecting both the strong interest from the sponsor community and the willingness of Member States to step up to the challenge of increased demand.
The 15 selected trials cover a broad range of therapeutic areas, including oncology and haematology (7 trials), neurology and neurodegenerative diseases (2), cardiovascular and pulmonary vascular disease (2), and immunology and inflammatory disease (2). Trials span all development phases, from Phase I to Phase III, and involve on average 7.33 participating Member States per procedure, with individual trials involving up to 14 Member States. 
First Completed Procedures Confirm Feasibility of 70-Day Target
Three procedures have been completed to date, all meeting or closely approximating the 70-calendar-day target set by FAST-EU*1. These results demonstrate that the 70-day timeline is operationally achievable across a diverse range of trial types, indication areas, and Member State constellations. 
Participating Member States and RMS Distribution
Twenty-six Member States and EEA countries are participating in FAST-EU. Reporting Member State distribution reflects the pan-European character of the initiative. RMS roles completed or ongoing include Italy, Denmark, the Netherlands, Germany (PEI), Finland, Poland, Sweden, Spain, Belgium, Norway, and the Czech Republic - with Romania, Hungary, Austria, and Portugal planned for upcoming procedures.
Relevance for the EU Biotech Act
he FAST-EU pilot was conceived in part as a proof of concept for the accelerated and coordinated clinical trial authorisation model anticipated under the EU Biotech Act. The pilot's timeline architecture - parallel validation, timelines based on full weeks, a single consolidated RFI round for Part I and a 70-day overall target - closely mirrors the  European Commission proposal for a revised authorisation procedure in the Biotech Act, aimed at creating a more competitive, agile and predictable European regulatory environment for clinical research.The interim results support the conclusion that this model is operationally feasible within the existing CTR framework, even where certain functionalities such timelines and separate validation processes are not yet supported by CTIS infrastructure. 
Next Steps
Ongoing evaluation will include qualitative findings from structured interviews with Reporting Member States on coordination effort, application of the reliance principle, and challenges for integration of Ethics Committees. A full pilot report will be published upon conclusion.
Sponsors wishing to submit an Expression of Interest for the FAST-EU pilot may contact the FAST-EU Coordination Office at FAST-EU@hma.eu. Further information is available in the FAST-EU External Guidance for Sponsors (Version 1.2, April 2026), published on the CTCG website.
The Clinical Trials Coordination Group (CTCG) is a standing working group of the Heads of Medicines Agencies (HMA), responsible for the operational implementation of the EU Clinical Trials Regulation. MedEthics EU under the auspices of the European Commission is the corresponding coordination body for Ethics Committees across the EU/EEA. 
1^ For one trial a deviation of one day related to the Easter public holiday period was noted and documented.


Article 11 workaround – MSCs intended to receive Part I only initial submission 
Sponsors are encouraged to include all MSCs where the clinical trial is planned to be conducted in the initial application to promote alignment of the Part I dossier (see Article 11 of the Clinical Trials Regulation on Part I only initial submission). 
However, in current CTIS sponsors cannot proceed with trial applications (substantial modifications, additional MSCs) if MSCs remain as Part I only.
A new Article 11 workaround (see the guidance published on the website on March 27 2026) applies from April 27 2026. It allows sponsors to include MSCs intended to receive Part I only by submitting Part II placeholders. The procedure also involves Part I only MSCs in reviews of subsequent SM Part I applications.
The trial is neither allowed to start nor recruit participants in MSCs where only placeholder data/documents Part II were submitted before actual Part II data/documents have been submitted and authorised.
For more background, see CTAG (Clinical Trials Coordination and Advisory Group) minutes to be published by the European Commission Mar 27 2026 from the Nov 27-28 2025 meeting at the Register of Commission expert groups and other similar entities, where CTAG is listed as group X03839
CTCG has organised a webinar on 15 April 2026, with more than 500 participants joining the meeting, during which it was explained how to apply this new approach, how to monitor these trials and where to find the supporting documents. It also provide insights into the new approach where to upload translated versions of patient facing documents into CTIS.
Please find the agenda, and the presentations on Translation of Patient Facing Documents in CTIS – New rules as well as Article 11 Work Around - Concept and supporting documents.
Meeting schedule for 2026
DateDate of the weekLocation09-10 February 2026Monday & Tuesday EMA09-10 March 2026Monday & Tuesday Virtual 13-14 April 2026Monday & TuesdayEMA20 May 2026WednesdayVirtual03-04 June 2026Tuesday & Wednesday Cyprus 08-09 July 2026 Wednesday & Thursday Virtual 09-10 September Wednesday & Thursday EMA08-09 October 2026Thursday & Friday Virtual 19-20 November 2026Thursday & FridayIreland 09-10 December 2026Wednesday & Thursday Virtual

]]></description>
                    <link>https://www.hma.eu//about-hma/working-groups/clinical-trials-coordination-group/clinical-trials-coordination-group.html#c7039</link>
                    <guid>https://www.hma.eu//about-hma/working-groups/clinical-trials-coordination-group/clinical-trials-coordination-group.html#c7039</guid>
                    <pubDate>Mon, 22 Jul 2024 15:26:00 +0200</pubDate>
                </item>
            
                <item>
                    <title><![CDATA[]]></title>
                    <description><![CDATA[FAST-EU Facilitating and Accelerating Strategic Clinical Trials in the EU/EEA
FAST-EU is an initiative by HMA, CTCG and MedEthics EU that enables an accelerated assessment of multinational clinical trials in the European Union. Operating within the EU Clinical Trials Regulation and CTIS, FAST-EU offers sponsors a predictable and efficient pathway for initial clinical trial applications.
The core feature of FAST-EU is a maximum overall timeline of 10 weeks (70 calendar days) from CTIS submission to final conclusion, including sponsor response times. This is achieved through parallel validation and assessment workflows and a strengthened role of the RMS, while maintaining scientific, safety and ethical standards. Ethics Committee opinions are fully integrated across all participating Member States.
Beyond accelerating individual applications, FAST-EU also functions as a structured learning and evidence-generation exercise. The pilot is designed to provide practical insights into the feasibility and challenges of the accelerated assessment model, thereby supporting the future implementation of the EU Biotech Act.
FAST-EU is a voluntary pilot with a planned duration of a year and a limited number of applications per month, so participation cannot be guaranteed.
The following Member States are participating in FAST-EU:
AT, BE, BG, CY, CZ, DE, DK, EE, ES, FI, FR, GR, HR, HU, IE, IT, LT, LV, NL, NO, PL, PT, RO, SE, SI, SK
Detailed procedural information is provided in the FAST-EU Sponsor Guide.
To enter a trial that is ready for submission in CTIS into FAST-EU , sponsors should express their interest by sending the Expression of Interest Template which can also be found as Annex to the FAST-EU Sponsor Guide via e-mail to FAST-EU@hma.eu. Submission windows are provided in the table below. Expression of Interest should indicate whether CTIS submission would be feasible in the first or second half of the relevant month.
‑A response can be expected within 5 business days.
MonthSubmission windowResponse June 20-21 May28 MayJuly22-23 June30 JuneAugust22-23 July30 JulySeptember20-21 August28 AugustOctober22-23 September30 SeptemberNovember22-23 October30 OctoberDecember19-20 November27 November
A total of 68 Expressions of interest have been received from the launch of the project with 15 clinical trials already selected for the accelerated assessment. In response to this high level of interest, and due to the substantial number of applications received, participating Member States agreed to accept more applications than initially planned. This collaborative decision underlines the commitment of the National Competent Authorities involved to keep supporting the project’s fast pace and broad participation. The following Reporting Member States have been selected for FAST EU until now:
AustriaBelgiumCzech RepublicDenmarkFinland  France Germany  Hungary ItalyNorwayNetherlandsPoland  PortugalSpain  Sweden   
These selections reflect efforts to distribute workload appropriately while maintaining feasibility across participating Member States. To support an equitable distribution of workload and to broaden Member State participation in the pilot, sponsors are encouraged to select RMS that have not yet been chosen in previous FAST-EU rounds whenever feasible.]]></description>
                    <link>https://www.hma.eu//about-hma/working-groups/clinical-trials-coordination-group/clinical-trials-coordination-group.html#c7860</link>
                    <guid>https://www.hma.eu//about-hma/working-groups/clinical-trials-coordination-group/clinical-trials-coordination-group.html#c7860</guid>
                    <pubDate>Wed, 21 Jan 2026 10:36:12 +0100</pubDate>
                </item>
            
                <item>
                    <title><![CDATA[]]></title>
                    <description><![CDATA[SUBSCRIBE to NEWSLETTER
30/4/2026      HMA newsletter April 2026
31/3/2026      HMA newsletter March 2026
26/2/2026      HMA newsletter February 2026
27/1/2026      HMA newsletter January 2026
22/12/2026    HMA newsletter December 2025
3/12/2025      HMA newsletter November 2025
20/10/2025    HMA newsletter October 2025
24/09/2025    HMA newsletter September 2025
15/07/2025    HMA newsletter July 2025
17/06/2025    HMA newsletter June 2025
14/05/2025    HMA newsletter May 2025
16/04/2025    HMA newsletter April 2025
16/04/2025    HMA Launches its Newsletter to provide updates about its coordinated work in the European regulatory network]]></description>
                    <link>https://www.hma.eu//about-hma/newsletter/newsletters.html#c7736</link>
                    <guid>https://www.hma.eu//about-hma/newsletter/newsletters.html#c7736</guid>
                    <pubDate>Thu, 10 Apr 2025 15:28:08 +0200</pubDate>
                </item>
            
        </channel>
    </rss>




    


        



